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doi:10.1016/j.jtcvs.2007.05.015bjectives: The objectives of this study were to compare the clinical features and
he outcomes after thymectomy between patients with and without thymoma and to
valuate the influence of thymectomy on the subsequent clinical course of myas-
henia gravis.
ethods: Between 1995 and 2003, 64 consecutive patients underwent thymectomy,
nd of these, 60 patients were followed up for at least 12 months postoperatively.
he study population was divided into 2 groups based on the presence of thymoma.
e performed a retrospective analysis to compare the neurologic outcomes of
hymectomy between patients with thymomatous myasthenia gravis and those with
onthymomatous myasthenia gravis.
esults: Twenty-four patients had a thymoma. No significant differences were
bserved between the 2 groups regarding the preoperative severity of myasthenia
ravis. There was no significant difference in the follow-up duration between the 2
roups. There was no significant difference in the overall remission rate between the
groups (P .064). The mean time required to reach a remission was 10.6 months and
3.5 months in the thymoma and nonthymoma groups, respectively. The mean duration
f remission was 43.1 months and 30.8 months in the thymoma and nonthymoma
roups, respectively. In the early phase of follow-up, more patients reached remission in
he thymoma group than those in the nonthymoma group (P  .040).
onclusions: Neurologic outcomes of the thymoma group were no worse than those
f the nonthymoma group. It is expected that earlier thymectomy is likely to result
n a better prognosis by shortening the disease period, even for patients with
onthymomatous myasthenia gravis.
yasthenia gravis (MG) is an autoimmune disorder that is caused by an
antibody-mediated attack directed against acetylcholine receptors at the
neuromuscular junction. Thymoma occurs in 24% to 38% of patients with
ate-onset MG.1,2 Both the clinical severity of MG and the outcomes after thy
omy are different between the patients with and those without thymoma. Thymoma
s considered a poor prognostic factor of MG because of either the more severe
ymptoms or the less responsiveness to treatment.3-10
Thymoma may be a source of autoantigen in thymomatous MG, and therefore we
ypothesized that the myasthenic symptoms of patients with thymoma would have
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TSetter response to thymectomy than would those of patients
ithout thymoma. The objectives of this study were to
ompare the clinical features and their outcomes after
hymectomy between patients with and those without thy-
oma and to evaluate the influence of thymectomy on the
ubsequent clinical course of MG.
aterials and Methods
etween January 1995 and December 2003, 64 consecutive pa-
ients with a diagnosis of MG underwent thymectomy at our
nstitution. Of these, 60 patients were followed up for at least 12
onths postoperatively, and they constituted the study population.
heir medical records were retrospectively reviewed to compare
he clinical characteristics and long-term results between the pa-
ients with thymoma and those without thymoma, and we focused
n the neurologic outcomes of MG. The study was reviewed and
pproved by the Institutional Review Board of the Sungkyunkwan
niversity.
The diagnosis of MG was primarily based on the clinical
eatures and confirmed by 1 or more of the following tests: the
ositive tensilon test, the repetitive nerve stimulation test, and
ssay for acetylcholine receptor antibody. All the patients under-
ent computed tomographic (CT) scanning of the chest to ascer-
ain whether they had pathologic abnormalities of the thymus. The
everity of MG was retrospectively evaluated at the time of diag-
osis, during the period of medical management, and immediately
efore the operation according to the clinical classification of the
edical Scientific Advisory Board of the Myasthenia Gravis
oundation of America (MGFA).11
Thymectomy was recommended when either thymoma or hy-
erplasia of the thymus was detected on the CT scan or when the
atients aged 19 through 69 years had generalized symptoms of
G. All thymectomies were performed transternally, as described
reviously, and every possible effort was made to eliminate all the
hymic tissue as completely as possible.7 A consistent protocol o
erioperative care was used, including preoperative stabilization
nd postoperative management of the patients.
A histopathologic examination was performed on all specimens
nd then reviewed by a pathologist. Thymomas were histologically
lassified based on the new World Health Organization classifica-
ion of Rosai and Sabin as type A (medullary), AB (mixed), B1
organoid), B2 (cortical), B3 (epithelial), or C (thymic carcinoma)
hymoma. For the patients with thymoma, pathologic staging was
one according to the scheme suggested by Masaoka and col-
eagues.12 Stage I was defined as macroscopically complet
ncapsulated thymomas, with no microscopically determined cap-
ular invasion; stage II was defined as macroscopic invasion into
he surrounding fatty tissue or mediastinal pleura or microscopic
nvasion into capsule; stage III was defined as macroscopic inva-
Abbreviations and Acronyms
CT  computed tomography
MG myasthenia gravis
MGFAMyasthenia Gravis Foundation of Americaion into neighboring organs (ie, pericardium, great vessels, and m
02 The Journal of Thoracic and Cardiovascular Surgery ● Septeung); stage IVa was defined as pleural or pericardial dissemina-
ion; and stage IVb was defined as lymphogenous or hematoge-
ous metastasis. Patients with advanced stages of thymoma re-
eived adjuvant radiation therapy or both adjuvant radiation
herapy and chemotherapy.
All the patients were regularly followed up at intervals of 3
onths for the first 2 years postoperatively and then every 6
onths thereafter. A detailed report of the MGFA classification
nd medications for each patient was obtained at every point of
ollow-up and then reviewed by a neurologist. The clinical out-
omes regarding MG were classified according to the MGFA
ostintervention status11: complete stable remission, pharmac-
ogic remission, improved, unchanged, and worse. The remission
ate was defined as the ratio of the number of patients in either
omplete or pharmacologic remission to the number of patients
hose information concerning the neurologic status was available
t each follow-up visit. A follow-up CT scan was performed to rule
ut the possibility of a recurrent thymic tumor in patients with
ustained neurologic symptoms.
The study population was divided into 2 groups based on the
resence of a thymoma. Descriptive statistics were used to de-
cribe the patients’ characteristics and outcomes. The normally
istributed continuous data were expressed as means  SD. Cat-
goric data were expressed as counts and proportions. The Student
test and the 2 or Fisher exact test were used to compare the
ontinuous and categoric variables, respectively.
esults
atient Profile
he clinical characteristics and operative techniques of the
tudy population are presented in Table 1. Twenty-
40%) patients turned out to have a thymoma. The thymoma
roup consisted of 8 men and 16 women with a mean age of
6.5  15.3 years. The nonthymoma group was comprised
f 10 men and 26 women with a mean age of 36.4  11.5
ears. The mean duration of preoperative symptoms was
.0  5.0 months for the patients with thymoma compared
ith 22.0  27.3 months for those without thymoma. No
ignificant differences were observed between the thymoma
roup and the nonthymoma group regarding the severity of
G immediately before the operation. The preoperative
ntiacetylcholine receptor antibody titer was 7.5  3.2
mol/L and 6.6  4.2 nmol/L in the thymoma and nonthy-
oma groups, respectively. In the nonthymoma group, 16
44.4%) patients required immunosuppression therapy pre-
peratively, whereas 5 (20.8%) patients of the thymoma
roup received immunosuppression therapy before their
perations.
perative Results
here was no in-hospital mortality. No patients experienced
ignificant complications related to the operation. Of the 24
atients who underwent thymectomy for both MG and
hymoma, 4 (16.7%) were treated for myasthenic crisis
ostoperatively, whereas none of the patients without thy-
oma experienced myasthenic crisis. The postoperative
mber 2007
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TSntiacetylcholine receptor antibody titer was 7.6  3.7
mol/L and 6.5  4.2 nmol/L in the thymoma and nonthy-
oma groups, respectively. A report of the pathologic find-
ngs was available for all the patients, which revealed hy-
erplasia of the thymus in 26 patients, thymoma in 24
atients, thymolipoma in 3 patients, fatty involution of the
hymus in 2 patients, and normal thymus in 1 patient.
mong the 24 patients who had both MG and thymoma, 13
54.2%) had stage I disease, 7 (29.2%) had stage II disease,
(12.5%) had stage III disease, and 1 (4.2%) had stage IV
isease. Except for the 1 patient with pleural dissemination,
here was no incomplete resection of the thymoma. Thirteen
54.2%) patients received adjuvant therapy for either inva-
ive thymoma or thymic carcinoma. There were no recur-
ences of thymic tumors, except for the 1 patient with stage
V thymic carcinoma. A repeat operation was not performed
n any group. The histologic classification of the specimens
nd the pathologic staging of thymoma are listed in Ta
eurologic Outcomes
ollow-up was completed for all the patients, with a mean
uration of 58.1 months (range, 15.4-133 months). There
as no significant difference in the follow-up duration
etween the 2 groups. During follow-up, 23 (95.8%) pa-
ients in the thymoma group achieved an asymptomatic
tate, as did 29 (80.6%) in the nonthymoma group, regard-
ess of the length of the symptom-free period. In the thy-
oma group 16 (66.7%) patients were asymptomatic at the
able 1. Clinical characteristics of the study population
All patients
n  60
ge at diagnosis, y (mean  SD) 39.3  14.3
ge at operation, y (mean  SD) 40.5  14.0
ale sex/female sex 18/42
uration of symptoms, n (%)
1 y 45 (75)
1 y 15 (25)
G classification, n (%)
Ocular 16 (27)
Generalized 44 (73)
GFA stage, n (%)
I 16 (27)
IIa 17 (28)
IIb 22 (37)
IIIa 1 (2)
V 4 (7)
GFA stage (mean  SD) 2.0  0.9
yasthenic crisis, n (%) 6 (10)
reoperative remission, n (%) 2 (3)
ChR Ab, nmol/L (mean  SD) 6.9 3.9
mmunosuppressants, n (%) 21 (35)
D, Standard deviation; MG, myasthenia gravis; MGFA, Myasthenia Graviast follow-up, and of these, 11 needed no medication for W
The Journal of Thoracic.
G. In the nonthymoma group 24 (66.7%) patients were
symptomatic at the last follow-up, and of these, 21 re-
uired no medication for MG. Among the thymoma group,
8 (75%) patients experienced either complete or pharmaco-
ogic remission during the follow-up period. Of these, 12
atients maintained the remission until the last follow-up visit,
hereas 6 had a relapse. On the other hand, among the non-
hymoma group, 25 (69.4%) patients reached either complete
r pharmacologic remission before the last follow-up visit. Of
hese, 20 patients remained in remission, whereas 5 relapsed
hereafter. There was no significant difference in the remission
ates between the 2 groups (P  .064). The time required to
each a remission was 10.6  9.7 months and 23.5  30.6
Thymoma () Thymoma ()
P valuen  24 n  36
46.4  15.2 34.6 11.7 .003
46.5  15.3 36.4 11.5 .009
8/16 10/26 .645
.002
23 (96) 22 (61)
1 (4) 14 (39)
.121
9 (38) 7 (19)
15 (62) 29 (81)
.824
9 (38) 7 (19)
4 (17) 13 (36)
8 (33) 14 (39)
1 (4) —
2 (8) 2 (6)
1.9 1.1 2.0 0.8 .826
3 (13) 3 (8) .675
0 (0) 2 (6) .512
7.5 3.2 6.6 4.2 .412
5 (21) 16 (44) .060
ndation of America; AChR Ab, acetylcholine receptor antibody.
able 2. Histologic classification and pathologic staging
f thymoma
WHO classification, n (%)
B1 5 (20.8)
B2 9 (37.5)
B2  B3 2 (8.3)
B3 7 (29.2)
C 1 (4.2)
Masaoka stage, n (%)
I 13 (54.2)
II 7 (29.2)
III 3 (12.5)
IV 1 (4.2)HO, World Health Organization.
and Cardiovascular Surgery ● Volume 134, Number 3 603
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TSonths in the thymoma and nonthymoma groups, respectively
P  .059). The mean duration of remission was 43.1  27.3
onths and 30.8  21.1 months in the thymoma and nonthy-
oma groups, respectively (P  .151). The remission rate of
igure 1. Comparison of the remission rates between the thy-
oma and nonthymoma groups.
able 3. Neurologic outcomes after thymectomy
All patients
n  60
U duration, mo (mean  SD) 58.1  28.5
Sx during FU, n (%) 52 (87)
yasthenic crisis, n (%) 4 (7)
ast FU visit, n (%)
Asymptomatic 40 (67)
Ocular MG 8 (13)
Generalized MG 12 (20)
emission rate (%)
Overall 72
At 1 y 40
At 2 y 45
At 3 y 52
At 4 y 51
At 5 y 50
uR, mo (mean  SD) 18.1  24.8
oR, mo (mean  SD) 36.0  27.5
elapse, n (%) 11 (26)
inal outcomes, n (%)
CR 23 (38)
PR 9 (15)
Improved 16 (27)
Unchanged 8 (13)
Worse 4 (7)
ChR Ab, nmol/L (mean  SD) 6.9  4.0
U, Follow-up; SD, standard deviation; ASx, asymptomatic;MG, myasthenia
emission; PR, pharmacologic remission; AChR Ab, acetylcholine receptor antib
04 The Journal of Thoracic and Cardiovascular Surgery ● Septehe thymoma group at 1, 2, 3, 4, and 5 years was 54.2%,
0.9%, 66.7%, 61.1%, and 61.5%, respectively (Figure 1). 
emission rate of the nonthymoma group at 1, 2, 3, 4, and 5
ears was 30.6%, 32.1%, 39.1%, 42.9%, and 41.2%, respec-
ively (Figure 1). There were no significant differences in
emission rates between the 2 groups, except for the 2-year rate
P .040). The data regarding the neurologic outcomes during
he follow-up period are summarized in Table 3. Compari
f the MGFA class and the percentages of asymptomatic or
eneralized patients with MG with all the patients are shown in
igures 2, 3, and 4.
iscussion
he relationship between MG and the thymus has been
ecognized for a number of years, because the thymus in
atients with MG often shows pathologic abnormalities,
uch as thymic follicular hyperplasia and thymic tumors.
pithelial tumor of the thymus (ie, thymoma) occurs in
pproximately 10% of patients with MG, and in turn, MG
ccurs in approximately 15% of patients with thymoma13
hen patients with MG also have a thymoma, their clinical
anifestations are significantly distinct from those seen in
he patients without thymomas. In comparison with patients
ithout thymomas, the onset of MG in patients with thy-
Thymoma ()
n  24
Thymoma ()
n  36 P value
63.0  23.4 54.8  31.6 .280
23 (96) 29 (81) .128
4 (17) — .022
16 (67) 24 (67) 1.000
3 (13) 5 (14) 1.000
5 (21) 7 (19) 1.000
75 69 .064
54 31 .067
61 32 .040
67 39 .068
61 43 .256
62 41 .269
10.6  9.7 23.5  30.6 .059
43.1  27.3 30.8  27.1 .151
6 (33) 5 (20) .321
.903
8 (33) 15 (42)
4 (17) 5 (14)
9 (38) 7 (19)
1 (4) 7 (19)
2 (8) 2 (6)
7.6  3.7 6.5  4.2 .371
; TuR, time until remission; DoR, duration of remission; CR, complete stablegravis
ody.
mber 2007
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G
TSomas tends to be late, with a peak incidence in the sixth
nd seventh decades, and this combined disease mostly
ffects men.5 Likewise, in our practice patients with M
ith thymoma were older than those without thymoma, and
en were more frequently affected in the thymoma group
han in the nonthymoma group.
Since Blalock and associates14 reported a remission o
eneralized MG after removal of a thymic tumor in 1939,
umerous studies have demonstrated the favorable out-
omes of thymectomy on the natural course of the disease,
nd thymectomy is currently considered to be effective for
reating MG.15 Many studies have been conducted to de-
igure 2. Comparison of the Myasthenia Gravis Foundation of
merica (MGFA) class between the thymoma and nonthymoma
roups.
igure 3. Comparison of the percentages of patients with gener-
lized myasthenia gravis (MG) between the thymoma and non-ghymoma groups.
The Journal of Thoracicine the prognostic factors of thymectomy, and a variety of
rognostic predictors have been identified, including age at
peration,6,9,10,12,16-18 the severity of MG,10,16,19 and the
reoperative duration of symptoms.3,6,7,10 Among these, th
resence of thymoma indicates a poor prognosis after
hymectomy for MG.3-10 Jaretzki and coworkers4 found a
ecreased remission rate and increased mortality among
atients with thymomas and MG. Masaoka and associate12
n their large study of 375 patients, observed that 67.2% of
he patients without thymomas achieved remission at 15
ears compared with 31.8% of the patients with thymomas.
hey suggested that the absence of thymoma was one of the
avorable prognostic factors.
In our study, however, we found that patients with thy-
omas appeared to have better neurologic outcomes after
hymectomy than did those without thymomas. In the early
hase of follow-up, and especially 2 years after the opera-
ion, considerably more patients reached a remission state in
he thymoma group than in the nonthymoma group (P 
040). The longer the duration of follow-up, the less was the
ifference in the remission rates between the 2 groups, with
he long-term results of the nonthymoma group showing
mprovement. Nevertheless, the thymoma group showed at
east no less favorable outcomes than did the nonthymoma
roup, even in the late phase. The overall remission rate of
he thymoma group was no lower than that of the nonthy-
oma group (75% vs 69%, P  .064). Additionally, not
nly did the patients with thymoma reach a remission earlier
10.6 vs 23.5 months, P  .059) but they also maintained it
onger (43.1 vs 30.8 months, P  .151) than did those
ithout thymomas. Despite this tendency, however, there
as no statistically significant difference between the 2
igure 4. Comparison of the percentages of asymptomatic pa-
ients between the thymoma and nonthymoma groups.roups. When the patients who achieved remission were
and Cardiovascular Surgery ● Volume 134, Number 3 605
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G
TSollowed up, there were no significant differences in the
elapse rates between the 2 groups. Our findings seem to
e quite different from the previous series in the literature,
hich regarded the presence of a thymoma as a poor prog-
ostic factor.
These results could be interpreted from several perspec-
ives. First, when the patients have both MG and thymoma, the
verall prognosis could be influenced by invasiveness of
he tumors, as well as by the neurologic symptoms. Most of
he patients in the thymoma group in our series had less
dvanced stages of tumor, which could have had less of an
dverse effect on the prognosis of MG.
Second, it has been reported that patients with thymoma
end to have more advanced MG preoperatively, and some
uthors speculated that the poor outcomes for patients with
hymomatous MG could be explained by this tendency. In our
ractice the severity of neurologic symptoms in the thy-
oma group was no more advanced than that in the non-
hymoma group, and this might have led to better results in
he thymoma group, which is in contrast to the past reports.
Third, it is likely that patients with thymomas undergo
hymectomy earlier than those without thymomas. When my-
sthenic patients are also given a diagnosis of thymoma,
rompt thymectomy is recommended for the treatment of a
hymoma per se. Neurologists or physicians could easily de-
ide to suggest an operation for patients with both MG and
hymoma. On the contrary, when there is no evidence of a
hymic tumor, then there could be a propensity to postpone
thymectomy or to continue medical treatment. In our study
3 of 24 patients with thymoma underwent thymectomy
ithin a year after a diagnosis of MG, whereas 14 of 36
atients without thymoma had to have MG for more than a
ear before their operations. Given that the short duration of
reoperative symptoms has been consistently considered a
ood prognostic factor in most series,3,6,7,10 the reason why
he patients with thymoma showed relatively favorable out-
omes in our series could be that they received thymectomy
lmost immediately after diagnosis. In the same context the
atients without thymoma would have achieved much better
utcomes if thymectomy had been recommended as early as
as done for the patients with thymoma.
This study demonstrated different results than did those
f the previous reports, and we tried to interpret the impli-
ations of our findings. Nonetheless, we could not reveal the
echanism of dissimilar responses to thymectomy between
he thymoma and nonthymoma groups. It is generally
nown that thymomatous MG is distinct from nonthymo-
atous MG as to the pathogenesis of disease. However, it is
till unclear how a thymoma plays a role for patients with
G, although it has been assumed that a thymoma could be
he substantial source of continued antigenic stimulation.
ad we performed antibody assay for various antigens otherhan the acetylcholine receptor, it would have been helpful
06 The Journal of Thoracic and Cardiovascular Surgery ● Septeo elucidate the differences between the 2 groups. In addi-
ion, because our data were retrospectively gathered and
hen analyzed, this study has important limitations. Further-
ore, the study population was rather too small to show the
ignificant difference in neurologic outcomes between the
hymoma and nonthymoma groups, and there were few
ases for which the relationship between relapse of MG and
ecurred thymoma could be investigated. If the patients had
xperienced recurrence of thymoma after a remission and
hen they had been followed by the relapse of MG, this
ould have been strong evidence that MG was provoked by
thymoma.
In conclusion, we evaluated the influence of thymomas
n the results of thymectomy for patients with MG by
omparing the neurologic outcomes between the thymoma
nd nonthymoma groups. Neurologic outcomes of the thy-
oma group were no worse than those of the nonthymoma
roup. It is expected that earlier thymectomy is likely to
esult in a better prognosis by shortening the disease period,
ven for patients with nonthymomatous MG. We believe
hat it is necessary to perform a prospective study under
linical circumstances that would include antibody assays
or the various antigens specific to thymomas, and thymo-
atous MG should be considered a different disease cate-
ory from nonthymomatous MG.
eferences
1. Hohlfeld R, Wekerle H. The thymus in myasthenia gravis. Neurol
Clin. 1994;12:331-42.
2. Wekerle H. The thymus in myasthenia gravis. Ann N Y Acad Sci.
1993;681:47-55.
3. Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, Fagerstrom RP,
Pozner J, et al. Effects of thymectomy in myasthenia gravis. Ann Surg.
1987;206:79-88.
4. Jaretzki A 3rd, Penn AS, Younger DS, Wolff M, Olarte MR, Lovelace
RE, et al. “Maximal” thymectomy for myasthenia gravis. Results.
J Thorac Cardiovasc Surg. 1988;95:747-57.
5. Hoosterhuis H. The natural course of myasthenia gravis: a long term
follow-up study. J Neurol Neurosurg Psychiatry. 1989;52:1121-7.
6. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini R.
Actuarial analysis of the occurrence of remissions following thymec-
tomy for myasthenia gravis in 400 patients. J Neurol Neurosurg
Psychiatry. 1991;54:406-11.
7. Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M,
et al. Extended thymectomy for myasthenia gravis patients: a 20-year
review. Ann Thorac Surg. 1996;62:853-9.
8. Cosi V, Romani A, Lombardi M, Raiola E, Bergamaschi R, Piccolo G,
et al. Prognosis of myasthenia gravis: a retrospective study of 380
patients. J Neurol. 1997;244:548-55.
9. Tellez-Zenteno JF, Remes-Troche JM, Garcia-Ramos G, Estanol B,
Garduno-Espinoza J. Prognostic factors of thymectomy in patients
with myasthenia gravis: a cohort of 132 patients. Eur Neurol. 2001;
46:171-7.
0. Budde JM, Morris CD, Gal AA, Mansour KA, Miller JI Jr. Predictors
of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg.
2001;72:197-202.
1. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC,
Penn AS, et al. Myasthenia gravis: recommendations for clinical
research standards. Task Force of the Medical Scientific Advisory
Board of the Myasthenia Gravis Foundation of America. Neurology.
2000;55:16-23.
mber 2007
11
1
1
1
1
1
1
Kim et al General Thoracic Surgery2. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of
thymomas with special reference to their clinical stages. Cancer.
1981;48:2485-92.
3. Osserman KE, Genkins G. Studies in myasthenia gravis: review of
twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971;
38:497-537.
4. Blalock A, Harvey A, Ford F, Lilienthal J Jr. The treatment of myasthenia
gravis by removal of the thymus gland. JAMA. 1941;117:1529-31.
5. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for auto-
immune myasthenia gravis (an evidence-based review): report of the
Quality Standards Subcommittee of the American Academy of Neu-The Journal of Thoracic6. Hatton PD, Diehl JT, Benedict DTD, Rheinlander HF, Johnson H,
Schrader JB, et al. Transsternal radical thymectomy for myasthenia
gravis: a 15-year review. Ann Thorac Surg. 1989;47:838-40.
7. Frist WH, Thirumalai S, Christopher BD, Merrill WH, Stewart JR,
Fenichel GM, et al. Thymectomy for the myasthenia gravis patient:
factors influencing outcome. Ann Thorac Surg. 1994;57:334-8.
8. Venuta F, Rendina EA, Giacomo TD, Rocca GD, Antonini G, Ciccone
AM, et al. Thymectomy for myasthenia gravis: a 27-year experience.
Eur J Cardiothorac Surg. 1999;15:621-5.
9. Nieto IP, Robledo JP, Pajuelo MC, Montes JA, Giron JG, Alonso JG,
et al. Prognostic factors for myasthenic gravis treated by thymectomy:G
TSrology. Neurology. 2000;55:7-15. review of 61 cases. Ann Thorac Surg. 1999;67:1568-71.and Cardiovascular Surgery ● Volume 134, Number 3 607
